These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 20393178)

  • 1. Aggressive lymphomas.
    Lenz G; Staudt LM
    N Engl J Med; 2010 Apr; 362(15):1417-29. PubMed ID: 20393178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
    Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
    Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.
    Koens L; Zoutman WH; Ngarmlertsirichai P; Przybylski GK; Grabarczyk P; Vermeer MH; Willemze R; Jansen PM; Schmidt CA; Tensen CP
    J Invest Dermatol; 2014 Jan; 134(1):290-292. PubMed ID: 23863863
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
    Saito B; Shiozawa E; Usui T; Nakashima H; Maeda T; Hattori N; Shimozuma J; Adachi D; Yamochi-Onizuka T; Takimoto M; Nakamaki T; Ota H; Tomoyasu S
    Leukemia; 2007 Dec; 21(12):2563-6. PubMed ID: 17597802
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel targeted therapies in diffuse large B-cell lymphoma.
    Mehta-Shah N; Younes A
    Semin Hematol; 2015 Apr; 52(2):126-37. PubMed ID: 25805592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma.
    Nowakowski GS; Vitolo U
    Future Oncol; 2017 Apr; 13(10):859-862. PubMed ID: 28183193
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
    Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
    Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B-cell lymphoma of germinal center and nongerminal center phenotypes presenting concurrently at the same anatomic site: intratumoral heterogeneity or composite lymphoma?
    Siddiqi IN; Shibata D
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):78-80. PubMed ID: 25153495
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
    Yang Y; Shaffer AL; Emre NC; Ceribelli M; Zhang M; Wright G; Xiao W; Powell J; Platig J; Kohlhammer H; Young RM; Zhao H; Yang Y; Xu W; Buggy JJ; Balasubramanian S; Mathews LA; Shinn P; Guha R; Ferrer M; Thomas C; Waldmann TA; Staudt LM
    Cancer Cell; 2012 Jun; 21(6):723-37. PubMed ID: 22698399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of the NF-κB Pathway in B-Lymphocyte Biology.
    Sasaki Y; Iwai K
    Curr Top Microbiol Immunol; 2016; 393():177-209. PubMed ID: 26275874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proximal signals controlling B-cell antigen receptor (BCR) mediated NF-kappaB activation.
    Moreno-García ME; Sommer KM; Bandaranayake AD; Rawlings DJ
    Adv Exp Med Biol; 2006; 584():89-106. PubMed ID: 16802601
    [No Abstract]   [Full Text] [Related]  

  • 17. Indications for peripheral light-chain revision and somatic hypermutation without a functional B-cell receptor in precursors of a composite diffuse large B-cell and Hodgkin's lymphoma.
    Rosenquist R; Menestrina F; Lestani M; Küppers R; Hansmann ML; Bräuninger A
    Lab Invest; 2004 Feb; 84(2):253-62. PubMed ID: 14688797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children.
    Oschlies I; Burkhardt B; Salaverria I; Rosenwald A; d'Amore ES; Szczepanowski M; Koch K; Hansmann ML; Stein H; Möller P; Reiter A; Zimmermann M; Rosolen A; Siebert R; Jaffe ES; Klapper W
    Haematologica; 2011 Feb; 96(2):262-8. PubMed ID: 20971819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
    Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E
    Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.